Futura Medical PLC Block Listing Six Monthly Return (2671V)
30 Noviembre 2023 - 9:10AM
UK Regulatory
TIDMFUM
RNS Number : 2671V
Futura Medical PLC
30 November 2023
Block Listing Six Monthly Return
30 November 2023
Futura Medical plc (AIM: FUM), the pharmaceutical company
developing innovative sexual health products, makes the following
update on its block listings, pursuant to AIM Rule 29 and Schedule
Six of the AIM Rules for Companies. All figures relate to options
over Ordinary Shares of 0.2 pence each (Ordinary Shares).
Name of applicant: Futura Medical Plc
Name of scheme(s): Unapproved Share Option Scheme
Unapproved Share Incentive Scheme
EMI Share Option Scheme
LTIP Scheme
---------------------------------------
Period of return: From: 1 June 2023 To: 30 November 2023
----------------------- ------------- ---- ------------------
Balance of unallotted securities under scheme(s) from previous return: 12,526,721
---------------------------------------
Plus: The amount by which the block scheme(s) has been increased since the LTIP: 10,590,675
date of the last
return (if any increase has been applied for):
---------------------------------------
Less: Number of securities issued/allotted under scheme(s) during period: USOS: nil
EMI: 756,000
LTIP: 1,578,731
---------------------------------------
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 20,782,665
---------------------------------------
Number and class of securities originally admitted and the date of admission USOS Total: 3,882,912
814,424 25 May 2011
1,202,280 8 October 2013
1,466,208 25 May 2017
400,000 30 May 2018
USIS Total: 425,000
425,000 30 November 2018
EMI Total: 8,112,088
1,520,576 25 May 2011
1,467,720 8 October 2013
1,893,792 25 May 2017
790,000 30 May 2018
1,340,000 30 November 2018
1,100,000 2 February 2023
LTIP Total: 15,035,617
4,444,942 2 February 2023
10,590,675 3 November 2023
---------------------------------------
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.futuramedical.com
Nominated Adviser and Sole Broker:
Liberum
Phil Walker / Ben Cryer
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Nick Bastin/ Jonathan Edwards/ Elena Bates
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 882 9621
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) technology. Each DermaSys(R)
formulation is separately patented and specifically tailored for
the selected indication and application, as well as being optimised
for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and
consumer healthcare markets as appropriate. Development and
commercialisation strategies are designed to maximise product
differentiation and value creation whilst minimising risk.
MED3000 is Futura's topical gel formulation that is a novel
treatment for erectile dysfunction (ED) through a unique
evaporative mode of action. Futura has conducted two Phase 3
studies using MED3000 in ED; FM57 study which enabled Futura to be
granted a CE Mark in 2021 and FM71 which enabled Futura to be
granted US marketing authorisation. Both studies demonstrated that
MED3000 presents an effective clinically proven treatment for ED
with a rapid speed of onset and a favourable benefit versus risk
profile ideally suited for an 'Over the Counter'
classification.
Eroxon(R) is FDA approved in the US, CE marked in Europe and
UKCA marked in the UK as a clinically proven topical treatment for
adult men with erectile dysfunction under the brand Eroxon(R) with
a key claim of "Helps you get an erection within 10 minutes".
Eroxon(R) is the agreed brand name in certain regions such as the
EU whereas MED3000 continues to be the internal code name used by
the Company and also in reference to countries where regulatory
approval or commercial distribution agreements have not yet been
achieved. www.eroxon.com
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange. www.futuramedical.com
.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BLRURVSROUUAOAA
(END) Dow Jones Newswires
November 30, 2023 10:10 ET (15:10 GMT)
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
